Treatment for H. pylori Infection

Diagnosis and Testing

A positive H. pylori test result can be trusted even during PPI therapy, as PPIs reduce bacterial load by increasing gastric pH but do not create false-positive results 1, 2
The mechanism of PPI interference works by decreasing bacterial load in the stomach, which leads to 10-40% false-negative rates across most testing modalities 1, 3, 2
False-positive results are particularly associated with serology and can occur with urea breath tests in specific circumstances 1
Achlorhydria can cause false-positive UBTs due to overgrowth of non-H. pylori urease-producing organisms 1, 2

Proceed with H. pylori eradication therapy based on the positive test result, regardless of PPI use or normal EGD findings 1, 2
A normal-appearing EGD does not exclude H. pylori infection, as the infection causes microscopic gastritis that may not be visible endoscopically 1

All H. pylori-infected individuals develop gastritis and are at risk for developing H. pylori-associated diseases ranging from dyspepsia to potentially life-threatening conditions including gastric cancer 1
Eradication of H. pylori halts the progression of chronic active gastritis to atrophic gastritis, which is the pathway to gastric cancer 1
The natural history shows exponential increase in gastric cancer risk with age, and eradication alters this natural history by halting the increase in risk 1

Do not withhold treatment based on suspicion of false-positive results from PPI use - this represents a fundamental misunderstanding of how PPIs affect H. pylori testing 1, 2
If you remain uncertain after a positive test, confirm with a stool antigen test rather than withholding treatment 1

PPIs do not produce false‑positive stool antigen results; they can only cause false‑negative outcomes in approximately 10 %–40 % of tests. This reflects the mechanism whereby PPIs raise gastric pH, reduce bacterial load, and diminish antigen shedding into stool. 4

When performed correctly, the H. pylori stool antigen assay demonstrates a sensitivity of 93.2 % and a specificity of 93.2 % for initial diagnosis. These values indicate excellent diagnostic accuracy for detecting active infection. 5

In regions where clarithromycin resistance exceeds 15 %, standard triple therapy achieves only 10 %–30 % eradication rates for resistant strains. Consequently, guidelines recommend either bismuth‑containing quadruple therapy or susceptibility testing (when endoscopy is feasible) to improve outcomes. 6

The same source also confirms the resistance threshold (>15 %) as the trigger for modifying the treatment approach. 4